Who are BOTOX® purified neurotoxin complex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DWC202405, DWC202314P, DWC202404, DWC202314P, DWC202313, DWC202314P, DWC202313, DWC202314, Onabotulinumtoxin A (BoNT), Intradetrusor Botox Injections.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/botox-purified-neurotoxin-complex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BOTOX® purified neurotoxin complex — Competitive Intelligence Brief

BOTOX® purified neurotoxin complex (BOTOX® purified neurotoxin complex) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin. Area: Neurology.

phase 2 Neurotoxin Botulinum toxin type A Neurology Small molecule Live · refreshed every 30 min

Target snapshot

BOTOX® purified neurotoxin complex (BOTOX® purified neurotoxin complex) — Allergan. Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BOTOX® purified neurotoxin complex TARGET	BOTOX® purified neurotoxin complex	Allergan	phase 2	Neurotoxin	Botulinum toxin type A
DWC202405, DWC202314P	DWC202405, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202404, DWC202314P	DWC202404, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202313, DWC202314P	DWC202313, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202313, DWC202314	DWC202313, DWC202314	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
Onabotulinumtoxin A (BoNT)	Onabotulinumtoxin A (BoNT)	Edgar LeClaire, MD	marketed	Neurotoxin; botulinum toxin serotype A	SNAP-25 (synaptosome-associated protein of 25 kDa)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin class)

Allergan · 2 drugs in this class
Aránzazu Vázquez Doce · 1 drug in this class
Ulthera, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BOTOX® purified neurotoxin complex — Competitive Intelligence Brief. https://druglandscape.com/ci/botox-purified-neurotoxin-complex. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab